ERRATUM Open Access



Erratum to: Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test

Eddy C. Hsueh¹, James R. DeBloom², Jonathan Lee³, Jeffrey J. Sussman⁴, Kyle R. Covington⁵, Brooke Middlebrook⁵, Clare Johnson⁵, Robert W. Cook^{5*}, Craig L. Slingluff Jr⁶ and Kelly M. McMasters⁷

Erratum

The original article [1] contained an error in Fig. 1 mistakenly carried forward by the Production team handling this article whereby the values denoting the 95% Confidence Intervals in the uppermost table had been omitted.

This error has now been corrected and the values returned.

Author details

¹Department of Surgery, St. Louis University, St. Louis, MO, USA. ²South Carolina Skin Cancer Center, Greenville, SC, USA. ³Northside Melanoma and Sarcoma Specialists of Georgia, Atlanta, GA, USA. ⁴Department of Surgery, University of Cincinnati Cancer Institute, Cincinnati, OH, USA. ⁵Castle Biosciences, Inc., 820 S. Friendswood Drive Suite 201, Friendswood, TX, USA. ⁶Department of Surgery and Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, USA. ⁷Department of Surgical Oncology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA.

Received: 14 September 2017 Accepted: 14 September 2017 Published online: 05 October 2017

Reference

 Hsueh EC, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017;10:152.

⁵Castle Biosciences, Inc., 820 S. Friendswood Drive Suite 201, Friendswood,





^{*} Correspondence: rcook@castlebiosciences.com




Fig. 1 Kaplan-Meier analysis of RFS (top), DMFS (middle), and OS (bottom) by GEP class. Significant separation of class 1 and class 2 risk (p < 0.0001) is observed for each endpoint. Solid line: class 1; dashed line: 2